Cumberland Pharmaceuticals Announces Assist-Ssc Trial Top-Line Results

By Reuters News

- Cumberland Pharmaceuticals Inc. CPIX.O:

  • CUMBERLAND PHARMACEUTICALS ANNOUNCES ASSIST-SSC TRIAL TOP-LINE RESULTS

  • CUMBERLAND PHARMACEUTICALS - IFETROBAN DEMONSTRATES SAFETY AND TOLERABILITY IN SYSTEMIC SCLEROSIS PATIENTS

  • CUMBERLAND PHARMACEUTICALS - IFETROBAN WELL TOLERATED; MOST GI ADVERSE EVENTS WERE MILD AND RESOLVED

  • CUMBERLAND PHARMACEUTICALS - NO SERIOUS ADVERSE EVENT RELATED TO IFETROBAN DURING 12-MONTH TREATMENT PERIOD

  • CUMBERLAND PHARMACEUTICALS - MODEST INCREASE IN MILD BLEEDING-RELATED ADVERSE EVENTS WITH IFETROBAN

Further company coverage: CPIX.O

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk